Skip to content

Menu

Network Sub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupportContact

Search

Close

Enter Search Terms

Benjamin R. Holt

ID: 1b83c155-2619-30fb-68c4

/

Claimed Record

/

Organization: Rothwell Figg

Article III Standing for an IPR Appeal Despite Patent Expiration and No Pending Litigation

PTAB Law Blog · June 4, 2019

Another Biosimilar Receives FDA Approval and Is Confronted with Litigation

Biosimilars Law Bulletin · May 28, 2019

Jury Finds Amgen Antibody Patents Not Invalid

Biosimilars Law Bulletin · March 18, 2019

Business as Usual for the USPTO and Federal Circuit Under the Partial Government Shutdown, At Least for Now

PTAB Law Blog · January 23, 2019

RFEM’s Biosimilars Inter Partes Review (IPR) Dashboard

Biosimilars Law Bulletin · November 14, 2018

Previous

12

Next

Practice Areas

Health Care and Life Sciences

Intellectual Property

Jurisdictions

Washington, D.C.

Publishing Record

Publisher Since 2017

Total Articles 10

Most Recent June 4, 2019

Cite This Author

Benjamin R. Holt, Rothwell Figg

LexBlog Author ID:

1b83c155-2619-30fb-68c4

www.lexblog.com/author/bholt

Contact

FirmRothwell Figg

Emailbholt@rfem.com

BlogsBiosimilars Law Bulletin

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS

About LexBlog
The Field We Built
Library at LexBlog
Our Beliefs
Our Team
Contact LexBlog

Disclaimer
Editorial Policy
Terms of Service

Get Started
Publishing Solutions
Compass

Submit a Request
Support Center
System Status

Copyright © 2026, LexBlog, Inc. All Rights Reserved.

Law blog design & platform by LexBlog